|
US2802005A
(en)
|
|
1957-08-06 |
|
S-eluorourace |
|
US2331725A
(en)
|
1941-01-31 |
1943-10-12 |
Lederle Lab Inc |
Preparation of 2-methyl-1,4-naphthoquinone
|
|
US3205220A
(en)
|
1961-10-26 |
1965-09-07 |
Lilly Co Eli |
Leurosidine and leurocristine and their production
|
|
CH514578A
(de)
|
1968-02-27 |
1971-10-31 |
Sandoz Ag |
Verfahren zur Herstellung von Glucosiden
|
|
GB1457632A
(en)
|
1974-03-22 |
1976-12-08 |
Farmaceutici Italia |
Adriamycins
|
|
DD159877A1
(de)
|
1981-06-12 |
1983-04-13 |
Wolfgang Krueger |
Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
|
|
OA07174A
(fr)
|
1981-08-24 |
1984-04-30 |
May & Baker Ltd |
Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
|
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
|
ES8604088A1
(es)
|
1985-06-14 |
1986-01-16 |
Espanola Farma Therapeut |
Procedimiento para la obtencion de un compuesto derivado de un acido dicarboxilico
|
|
FR2601675B1
(fr)
|
1986-07-17 |
1988-09-23 |
Rhone Poulenc Sante |
Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
|
|
FR2601676B1
(fr)
|
1986-07-17 |
1988-09-23 |
Rhone Poulenc Sante |
Procede de preparation du taxol et du desacetyl-10 taxol
|
|
US5004758A
(en)
|
1987-12-01 |
1991-04-02 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
|
|
IL96531A
(en)
|
1989-12-11 |
1995-08-31 |
Univ Princeton |
History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
|
|
US5369108A
(en)
|
1991-10-04 |
1994-11-29 |
Sloan-Kettering Institute For Cancer Research |
Potent inducers of terminal differentiation and methods of use thereof
|
|
WO1994006802A1
(fr)
|
1992-09-18 |
1994-03-31 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Compose de thienodiazepine et son utilisation medicinale
|
|
TW438775B
(en)
|
1995-04-07 |
2001-06-07 |
Pharmacia & Upjohn Co Llc |
Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
|
|
US6174905B1
(en)
|
1996-09-30 |
2001-01-16 |
Mitsui Chemicals, Inc. |
Cell differentiation inducer
|
|
JP3354090B2
(ja)
|
1996-09-30 |
2002-12-09 |
シエーリング アクチエンゲゼルシャフト |
分化誘導剤
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
GB0108591D0
(en)
|
2001-04-05 |
2001-05-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
ES2382377T3
(es)
|
2003-05-30 |
2012-06-07 |
Gemin X Pharmaceuticals Canada Inc. |
Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
|
|
WO2005049593A2
(en)
|
2003-11-13 |
2005-06-02 |
Abbott Laboratories |
N-acylsulfonamide apoptosis promoters
|
|
DK1730119T3
(da)
|
2004-03-23 |
2008-08-11 |
Pfizer Prod Inc |
Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
|
|
US7893278B2
(en)
|
2004-06-17 |
2011-02-22 |
Hoffman-La Roche Inc. |
CIS-imidazolines
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
AU2005277223C1
(en)
|
2004-08-20 |
2009-05-21 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
|
|
ES2377430T3
(es)
|
2004-09-02 |
2012-03-27 |
Genentech, Inc. |
Inhibidores piridílicos de la señalización de hedgehog
|
|
WO2006071608A2
(en)
|
2004-12-16 |
2006-07-06 |
President And Fellows Of Harvard College |
Histone demethylation mediated by the nuclear amine oxidase homolog lsd1
|
|
ES2349544T3
(es)
|
2005-02-18 |
2011-01-04 |
Universitätsklinikum Freiburg |
Control de la expresión génica dependiente de receptores de andrógenos inhibiendo la actividad de amina oxidasa de la demetilasa lisina-específica (lsd1).
|
|
HRP20100678T1
(hr)
|
2005-03-29 |
2011-02-28 |
Icos Corporation |
Derivati heteroariluree korisni kao inhibitori chk1
|
|
TWI375673B
(en)
|
2005-04-11 |
2012-11-01 |
Abbott Lab |
1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
|
|
PL1888550T3
(pl)
|
2005-05-12 |
2014-12-31 |
Abbvie Bahamas Ltd |
Promotory apoptozy
|
|
WO2007015632A1
(en)
|
2005-08-04 |
2007-02-08 |
Cgk Co., Ltd. |
Atm and atr inhibitor
|
|
WO2007021839A2
(en)
|
2005-08-10 |
2007-02-22 |
Johns Hopkins University |
Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
|
|
NL2000613C2
(nl)
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazoolpyrazinederivaten.
|
|
CL2007003244A1
(es)
|
2006-11-16 |
2008-04-04 |
Millennium Pharm Inc |
Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
|
|
EP2142287A4
(en)
|
2007-04-13 |
2012-05-23 |
Univ Johns Hopkins |
INHIBITORS OF LYSINPECIFIC DEMETHYLASE
|
|
US8642809B2
(en)
|
2007-09-25 |
2014-02-04 |
Topotarget Uk Ltd. |
Methods of synthesis of certain hydroxamic acid compounds
|
|
JP2011520921A
(ja)
|
2008-05-16 |
2011-07-21 |
ファルマ・マール・ソシエダード・アノニマ |
抗腫瘍アルカロイドとの併用療法
|
|
WO2010011845A2
(en)
|
2008-07-24 |
2010-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods of preventing or treating viral infection or reactivation after latency in a host using inhibitors of the lsd1 protein
|
|
PE20110292A1
(es)
|
2008-09-17 |
2011-05-17 |
Novartis Ag |
Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida
|
|
WO2010043721A1
(en)
|
2008-10-17 |
2010-04-22 |
Oryzon Genomics, S.A. |
Oxidase inhibitors and their use
|
|
US8993808B2
(en)
|
2009-01-21 |
2015-03-31 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
WO2010138588A2
(en)
|
2009-05-26 |
2010-12-02 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
|
EP2258865A1
(en)
|
2009-06-05 |
2010-12-08 |
Universitätsklinikum Freiburg |
Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
|
|
JPWO2010143582A1
(ja)
|
2009-06-11 |
2012-11-22 |
公立大学法人名古屋市立大学 |
フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤
|
|
AR077014A1
(es)
|
2009-06-19 |
2011-07-27 |
Lilly Co Eli |
Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
|
|
EP2467359A4
(en)
|
2009-08-18 |
2013-01-09 |
Univ Johns Hopkins |
(BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH
|
|
US8859555B2
(en)
|
2009-09-25 |
2014-10-14 |
Oryzon Genomics S.A. |
Lysine Specific Demethylase-1 inhibitors and their use
|
|
EP2486002B1
(en)
|
2009-10-09 |
2019-03-27 |
Oryzon Genomics, S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
|
GB0919432D0
(en)
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Use
|
|
PH12012501492B1
(en)
|
2010-01-22 |
2020-01-24 |
Acetylon Pharmaceuticals Inc |
Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
WO2011106106A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
US20130197088A1
(en)
|
2010-03-12 |
2013-08-01 |
Robert A. Casero, JR. |
Compositions and Methods for Combinations of Oligoamines with 2-Difluoromethylornithine (DFMO)
|
|
CA2796726C
(en)
|
2010-04-19 |
2021-02-16 |
Oryzon Genomics S.A. |
Lysine specific demethylase-1 inhibitors and their use
|
|
BR112012027062B8
(pt)
|
2010-04-20 |
2021-05-25 |
Fond Ieo |
composto, processo para a preparação de um composto e usos do mesmo
|
|
JP5864546B2
(ja)
|
2010-05-07 |
2016-02-17 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ |
インダゾール
|
|
EA023788B1
(ru)
|
2010-05-07 |
2016-07-29 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Производные индола и фармацевтические композиции на их основе
|
|
CN103119160B
(zh)
|
2010-05-14 |
2016-06-01 |
达那-法伯癌症研究所 |
用于调节代谢的组合物和方法
|
|
BR112013002164B1
(pt)
|
2010-07-29 |
2021-11-09 |
Oryzon Genomics S.A. |
Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
|
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
|
WO2012034116A2
(en)
|
2010-09-10 |
2012-03-15 |
The Johns Hopkins University |
Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
|
|
US20130303545A1
(en)
|
2010-09-30 |
2013-11-14 |
Tamara Maes |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
GB201112607D0
(en)
|
2011-07-22 |
2011-09-07 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
WO2012075381A1
(en)
|
2010-12-03 |
2012-06-07 |
Epizyme, Inc. |
Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
|
|
EP2712316A1
(en)
|
2011-02-08 |
2014-04-02 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
|
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
AU2012220620A1
(en)
|
2011-02-23 |
2013-10-03 |
Icahn School Of Medicine At Mount Sinai |
Inhibitors of bromodomains as modulators of gene expression
|
|
WO2012118812A2
(en)
|
2011-02-28 |
2012-09-07 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
TWI530489B
(zh)
|
2011-03-22 |
2016-04-21 |
必治妥美雅史谷比公司 |
雙（氟烷基）－１，４－苯二氮呯酮化合物
|
|
PH12013501871A1
(en)
|
2011-03-25 |
2019-06-03 |
Glaxosmithkline Ip No 2 Ltd |
Cyclopropylamines as lsd1 inhibitors
|
|
JO3363B1
(ar)
|
2011-04-13 |
2019-03-13 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
US20140296255A1
(en)
|
2011-05-19 |
2014-10-02 |
Oryzong Genomics, S.A. |
Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
|
|
US20140329833A1
(en)
|
2011-05-19 |
2014-11-06 |
Oryzon Genomics, S.A |
Lysine demethylase inhibitors for inflammatory diseases or conditions
|
|
AR087107A1
(es)
|
2011-07-27 |
2014-02-12 |
Lilly Co Eli |
Compuesto inhibidor de la señalizacion de la trayectoria notch
|
|
PE20141202A1
(es)
|
2011-08-09 |
2014-10-03 |
Takeda Pharmaceutical |
Compuesto de ciclopropanoamina
|
|
SI2744330T1
(sl)
|
2011-08-15 |
2020-11-30 |
University Of Utah Research Foundation |
Substituirani (E)-N'-(1-feniletiliden) benzohidrazidni analogi kot inhibitorji histon-demetilaze
|
|
JP6046154B2
(ja)
*
|
2011-10-20 |
2016-12-14 |
オリソン ヘノミクス エセ． アー． |
Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
|
|
EP2768805B1
(en)
|
2011-10-20 |
2020-03-25 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
JP5989805B2
(ja)
|
2012-02-10 |
2016-09-07 |
コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
メチル基変更酵素の調節物質、組成物及びその使用
|
|
US9828344B2
(en)
|
2012-06-01 |
2017-11-28 |
LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG FRITZ-LIPMANN-INSTITUT e.V. (FLI) |
Inhibitors of the notch signaling pathway and secretion for use in medicine
|
|
CA2887598A1
(en)
|
2012-10-12 |
2014-04-17 |
Takeda Pharmaceutical Company Limited |
Cyclopropanamine compound and use thereof
|
|
WO2014084298A1
(ja)
|
2012-11-28 |
2014-06-05 |
京都府公立大学法人 |
リシン構造を有するｌｓｄ1選択的阻害薬
|
|
WO2014085613A1
(en)
|
2012-11-30 |
2014-06-05 |
Mccord Darlene E |
Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
|
|
EP2740474A1
(en)
|
2012-12-05 |
2014-06-11 |
Instituto Europeo di Oncologia S.r.l. |
Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
|
|
JP2016510039A
(ja)
|
2013-02-28 |
2016-04-04 |
ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ |
ブロモドメイン阻害剤によるヒトサイトメガロウイルス感染および疾患の治療方法
|
|
WO2014164867A1
(en)
|
2013-03-11 |
2014-10-09 |
Imago Biosciences |
Kdm1a inhibitors for the treatment of disease
|
|
JP2016517434A
(ja)
|
2013-03-14 |
2016-06-16 |
エピザイム，インコーポレイティド |
癌を処置するための併用療法
|
|
WO2014194280A2
(en)
|
2013-05-30 |
2014-12-04 |
The Board of Regents of the Nevada System of Higher Education on behalf of the University of |
Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells
|
|
BR112015032113B1
(pt)
|
2013-06-19 |
2019-01-29 |
University Of Utah Research Foundation |
análogos de (e)-n’-(1-feniletilideno)benzohidrazida substituídos como inibidores de histona demetilase
|
|
EP2829284A1
(en)
|
2013-07-22 |
2015-01-28 |
Deutsches Krebsforschungszentrum |
Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor
|
|
ES2734209T3
(es)
|
2013-08-06 |
2019-12-04 |
Imago Biosciences Inc |
Inhibidores de KDM1A para el tratamiento de enfermedades
|
|
WO2015031564A2
(en)
|
2013-08-30 |
2015-03-05 |
University Of Utah |
Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
|
|
CA2931263A1
(en)
|
2013-12-06 |
2015-06-11 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
CA3161836A1
(en)
|
2013-12-11 |
2015-06-18 |
Celgene Quanticel Research, Inc. |
Inhibitors of lysine specific demethylase-1
|
|
WO2015120281A1
(en)
|
2014-02-07 |
2015-08-13 |
Musc Foundation For Research Development |
Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators
|
|
EP3105219B9
(en)
|
2014-02-13 |
2018-10-03 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
JP6602779B2
(ja)
|
2014-02-13 |
2019-11-06 |
インサイト・コーポレイション |
Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
|
|
EP3105218B1
(en)
|
2014-02-13 |
2019-09-25 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
CA2941716A1
(en)
|
2014-03-07 |
2015-09-11 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
|
MY180575A
(en)
|
2014-04-11 |
2020-12-02 |
Takeda Pharmaceuticals Co |
Cyclopropanamine compound and use thereof
|
|
KR102400920B1
(ko)
|
2014-05-01 |
2022-05-20 |
셀젠 콴티셀 리서치, 인크. |
리신 특이적 데메틸라제-1의 억제제
|
|
WO2015181380A1
(en)
|
2014-05-30 |
2015-12-03 |
Ieo - Istituto Europeo Di Oncologia S.R.L. |
Cyclopropylamine compounds as histone demethylase inhibitors
|
|
DK3160956T3
(da)
|
2014-06-27 |
2020-08-31 |
Celgene Quanticel Res Inc |
Inhibitorer af lysin-specifik demethylase-1
|
|
FI3511319T3
(fi)
|
2014-07-03 |
2023-07-20 |
Celgene Quanticel Res Inc |
Lysiinispesifisen demetylaasi-1:n inhibiittoreita
|
|
JP6525422B2
(ja)
|
2014-07-03 |
2019-06-05 |
セルジーン クオンティセル リサーチ，インク． |
リジン特異的なデメチラーゼ−１の阻害剤
|
|
US9695167B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
|
|
US9695180B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
|
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
|
WO2016007731A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Imidazopyridines and imidazopyrazines as lsd1 inhibitors
|
|
AU2015301746A1
(en)
*
|
2014-08-13 |
2017-02-16 |
Celgene Corporation |
Combination therapy for treating cancer
|
|
EP2993175A1
(en)
|
2014-09-05 |
2016-03-09 |
IEO - Istituto Europeo di Oncologia Srl |
Thienopyrroles as histone demethylase inhibitors
|
|
AU2015311805B2
(en)
|
2014-09-05 |
2020-04-02 |
Celgene Quanticel Research, Inc. |
Inhibitors of lysine specific demethylase-1
|
|
WO2016123387A1
(en)
|
2015-01-30 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CA2976350C
(en)
|
2015-02-12 |
2023-09-19 |
Hugh Young Rienhoff, Jr. |
Kdm1a inhibitors for the treatment of disease
|
|
CN106146361A
(zh)
|
2015-03-16 |
2016-11-23 |
四川大学 |
茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
|
|
EP3277689B1
(en)
|
2015-04-03 |
2019-09-04 |
Incyte Corporation |
Heterocyclic compounds as lsd1 inhibitors
|
|
CN106045862B
(zh)
|
2015-04-10 |
2019-04-23 |
上海迪诺医药科技有限公司 |
环丙胺类螺(杂)环化合物、其药物组合物及应用
|
|
US10526287B2
(en)
|
2015-04-23 |
2020-01-07 |
Constellation Pharmaceuticals, Inc. |
LSD1 inhibitors and uses thereof
|
|
EP3090998A1
(en)
|
2015-05-06 |
2016-11-09 |
F. Hoffmann-La Roche AG |
Solid forms
|
|
AU2016275702A1
(en)
|
2015-06-12 |
2017-12-21 |
Oryzon Genomics, S.A. |
Biomarkers associated with LSD1 inhibitors and uses thereof
|
|
WO2017004519A1
(en)
|
2015-07-02 |
2017-01-05 |
University Of Utah Research Foundation |
Substituted benzohydrazide analogs as histone demethylase inhibitors
|
|
WO2017013061A1
(en)
|
2015-07-17 |
2017-01-26 |
Oryzon Genomics, S.A. |
Biomarkers associated with lsd1 inhibitors and uses thereof
|
|
MY189367A
(en)
|
2015-08-12 |
2022-02-08 |
Incyte Corp |
Salts of an lsd1 inhibitor
|
|
CN105233292B
(zh)
*
|
2015-10-19 |
2018-03-13 |
中国科学院北京基因组研究所 |
Ory‑1001联合放疗和化疗用于治疗人三阴性乳腺癌的用途
|
|
CN105541806A
(zh)
|
2015-12-25 |
2016-05-04 |
中国药科大学 |
巴比妥酸类化合物、制备方法及其应用
|
|
CN105924362B
(zh)
|
2016-02-05 |
2018-08-17 |
上海龙翔生物医药开发有限公司 |
芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途
|
|
ES3057783T3
(en)
*
|
2016-03-15 |
2026-03-04 |
Oryzon Genomics Sa |
Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
|
|
CA3017408C
(en)
|
2016-03-15 |
2025-08-19 |
Oryzon Genomics, S.A. |
LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS
|
|
WO2017158136A1
(en)
|
2016-03-16 |
2017-09-21 |
Oryzon Genomics, S.A. |
Methods to determine kdm1a target engagement and chemoprobes useful therefor
|
|
CN106045881B
(zh)
|
2016-05-26 |
2017-10-31 |
新乡医学院 |
一类白藜芦醇衍生物、其制备方法及作为lsd1抑制剂的应用
|